Factors associated with an inconclusive result from commercial homologous recombination deficiency testing in ovarian cancer
Surgical tissue was more likely to yield a conclusive HRD test result versus other sources of epithelial ovarian cancer tissue acquisition. When feasible, laparoscopic biopsy before initiation of neoadjuvant chemotherapy may increase the likelihood of obtaining interpretable HRD test results.
Authors
- Qin Zhou (ORCID: https://orcid.org/0000-0001-5334-7188)
- Rachel N. Grisham (ORCID: https://orcid.org/0000-0002-8631-9324)
- Anusha Adkoli (ORCID: https://orcid.org/0000-0003-2370-0248)
- Lora H. Ellenson (ORCID: https://orcid.org/0000-0001-9127-6982)
- Britta Weigelt (ORCID: https://orcid.org/0000-0001-9927-1270)
- S. Dennis (ORCID: https://orcid.org/0000-0002-3105-8913)
- Roisin E. O’Cearbhaill (ORCID: https://orcid.org/0000-0001-8217-4554)
- Carol Aghajanian (ORCID: https://orcid.org/0000-0003-0851-3225)
- Ying L. Liu (ORCID: https://orcid.org/0000-0001-5790-851X)
- Mackenzie W. Sullivan (ORCID: https://orcid.org/0000-0003-0254-1137)
- Yukio Sonoda (ORCID: https://orcid.org/0000-0001-9684-5291)
- Stephen Graves
- Alexia Iasonos
Institutions
- Robert Wood Johnson University Hospital (US)
- Memorial Sloan Kettering Cancer Center (US)
- Cornell University (US)
Publication Details
- Journal
- Cancer
- Published
- 2024-08-16
- DOI
- https://doi.org/10.1002/cncr.35523
- Citations
- 5
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 1.41
Funders
- Breast Cancer Research Foundation
- AstraZeneca
- GlaxoSmithKline
- Gilead Sciences
- Memorial Sloan-Kettering Cancer Center
- Ludwig Institute for Cancer Research
- Regeneron Pharmaceuticals
- Atara Biotherapeutics
- Cycle for Survival
- NRG Oncology
- Syndax Pharmaceuticals
- Cardinal Health
- Natera
- Springworks Therapeutics
- Eisai
- Aptitude Health
- National Institutes of Health
- Genentech
- Juno Therapeutics
- National Cancer Institute